Indivior PLC has been added to the S&P SmallCap 600® index, a significant milestone for the company.
The inclusion in the index reflects Indivior's business profile alignment and capital markets presence.
Indivior is committed to expanding SUBLOCADE®, their leading long-acting injectable treatment for opioid use disorder.
Inclusion in S&P SmallCap 600
Indivior's addition to the S&P SmallCap 600 index signifies recognition of its market performance.
Business Growth Focus
Indivior aims to leverage its operating model to grow SUBLOCADE® and enhance its presence in the U.S. market.
Opioid Treatment Innovation
Indivior's dedication to developing medicines for opioid use disorder emphasizes their commitment to patient treatment outcomes.
- The addition to the S&P SmallCap 600 index enhances Indivior's visibility and positions them among well-performing small-cap companies.
- Investors may view Indivior's inclusion as a positive indicator of the company's financial strength and growth potential.
Indivior's inclusion in the S&P SmallCap 600 index underscores their continued dedication to innovation in opioid use disorder treatment and strategic business growth.